Avidity Biosciences Plans to Postpone and Reconvene Stockholder Meeting amid Upcoming Merger Avidity Biosciences announces plan to adjourn its special stockholder meeting and convene again on February 26, 2026, for merger proceedings.

Avidity Biosciences Plans to Postpone and Reconvene Stockholder Meeting amid Upcoming Merger #San_Diego #Avidity_Biosciences #Novartis_AG #RNA

Investigation Launched into Avidity Biosciences' Proposed Sale to Novartis AG Monteverde & Associates PC has announced an investigation into Avidity Biosciences Inc. regarding its planned sale to Novartis AG, focusing on the fairness of the deal.

Investigation Launched into Avidity Biosciences' Proposed Sale to Novartis AG #United_States #New_York #Monteverde_Associates #Avidity_Biosciences #Novartis_AG

Tourmaline Bio, Inc. Shareholder Investigation Launched by M&A Class Action Firm M&A Class Action Firm investigates Tourmaline Bio's sale to Novartis AG, questioning the fairness of the proposed cash offer to shareholders.

Tourmaline Bio, Inc. Shareholder Investigation Launched by M&A Class Action Firm #United_States #New_York #M&A_Class_Action #Novartis_AG #Tourmaline_Bio

April Highlights: Key Health Press Releases Reshaping the Industry Landscape Discover the top health press releases from April, featuring groundbreaking medical studies and significant industry updates from key players like Eli Lilly and Crunch Fitness.

April Highlights: Key Health Press Releases Reshaping the Industry Landscape #Crunch_Fitness #Eli_Lilly #Novartis_AG

Regulus Therapeutics to Be Acquired by Novartis AG for Up to $1.7 Billion Regulus Therapeutics has announced its acquisition by Novartis for $7.00 per share, potentially totaling $1.7 billion with contingent rights.

Regulus Therapeutics to Be Acquired by Novartis AG for Up to $1.7 Billion #USA #San_Diego #Regulus_Therapeutics #farabursen #Novartis_AG